Scott N. Boyle's Insider Trades & SAST Disclosures
Scott N. Boyle's most recent trade in C4 Therapeutics Inc was a trade of 84,700 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Feb. 13, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Scott N. Boyle.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| C4 Therapeutics Inc | Scott N. Boyle | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 84,700 | 84,700 | - | - | Stock Option (Right to Buy) | |
| C4 Therapeutics Inc | Scott N. Boyle | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 56,500 | 111,332 | - | 0 | Common Stock | |
| C4 Therapeutics Inc | Scott N. Boyle | Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.18 per share. | 13 Feb 2025 | 2,368 | 108,474 | - | 3.2 | 7,530 | Common Stock |
| C4 Therapeutics Inc | Scott N. Boyle | Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.20 per share. | 13 Feb 2025 | 1,735 | 54,832 | - | 3.2 | 5,552 | Common Stock |
| C4 Therapeutics Inc | Scott N. Boyle | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 3.15 per share. | 13 Feb 2025 | 669 | 107,805 | - | 3.1 | 2,107 | Common Stock |
| C4 Therapeutics Inc | Scott N. Boyle | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 3.15 per share. | 13 Feb 2025 | 490 | 110,842 | - | 3.2 | 1,544 | Common Stock |
| C4 Therapeutics Inc | Scott N. Boyle | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Nov 2024 | 3,750 | 57,669 | - | - | Common Stock | |
| C4 Therapeutics Inc | Scott N. Boyle | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Nov 2024 | 3,750 | 10,500 | - | - | Performance Restricted Stock Units | |
| C4 Therapeutics Inc | Scott N. Boyle | Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.04 per share. | 07 Nov 2024 | 1,102 | 56,567 | - | 6.0 | 6,656 | Common Stock |
| C4 Therapeutics Inc | Scott N. Boyle | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Sep 2024 | 2,250 | 14,250 | - | - | Performance Restricted Stock Units | |
| C4 Therapeutics Inc | Scott N. Boyle | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Sep 2024 | 2,250 | 54,580 | - | - | Common Stock | |
| C4 Therapeutics Inc | Scott N. Boyle | Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.36 per share. | 16 Sep 2024 | 661 | 53,919 | - | 6.4 | 4,204 | Common Stock |
| C4 Therapeutics Inc | Scott N. Boyle | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2024 | 115,000 | 115,000 | - | - | Stock Option (Right to Buy) | |
| C4 Therapeutics Inc | Scott N. Boyle | Chief Business Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 07 Mar 2024 | 115,000 | 0 | - | - | Stock Option (Right to Buy) | |
| C4 Therapeutics Inc | Boyle Scott N. | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 122,800 | 122,800 | - | - | Stock Option (Right to Buy) | |
| C4 Therapeutics Inc | Scott Boyle N. | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 27,300 | 52,330 | - | 0 | Common Stock | |
| C4 Therapeutics Inc | Boyle N. Scott | Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.53 per share. | 13 Feb 2024 | 1,735 | 25,030 | - | 6.5 | 11,330 | Common Stock |
| C4 Therapeutics Inc | Scott N. Boyle | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Aug 2023 | 2,250 | 16,500 | - | - | Performance Restricted Stock Units | |
| C4 Therapeutics Inc | Scott N. Boyle | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Aug 2023 | 2,250 | 27,426 | - | - | Common Stock | |
| C4 Therapeutics Inc | Scott N. Boyle | Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.93 per share. | 30 Aug 2023 | 661 | 26,765 | - | 2.9 | 1,937 | Common Stock |
| C4 Therapeutics Inc | Scott N. Boyle | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 90,000 | 90,000 | - | - | Stock Option (Right to Buy) | |
| C4 Therapeutics Inc | Scott N. Boyle | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 20,000 | 25,176 | - | 0 | Common Stock | |
| C4 Therapeutics Inc | Scott N. Boyle | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2023 | 3,750 | 18,750 | - | - | Performance Restricted Stock Units | |
| C4 Therapeutics Inc | Scott N. Boyle | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2023 | 3,750 | 6,398 | - | - | Common Stock | |
| C4 Therapeutics Inc | Scott N. Boyle | Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.78 per share. | 30 Jan 2023 | 1,222 | 5,176 | - | 7.8 | 9,507 | Common Stock |
| C4 Therapeutics Inc | Scott N. Boyle | Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.01 per share. | 26 May 2022 | 1,102 | 2,648 | - | 7.0 | 7,725 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges